<qa>  What is the name of the anti-cytotoxic T-lymphocyte antigen 4?- Patients may have had prior systemic therapy in the adjuvant setting e.g. interferon, BRAF, or mitogen-activated protein kinase MEK agents; patients may have had prior anti-cytotoxic T-lymphocyte antigen 4 CTLA-4 in the adjuvant setting, if at least one year from last dose of treatment has passed prior to beginning treatment; patients may not have had any prior programmed cell death PD-1PD-ligand PD-L1 agent in the adjuvant setting 